March 30 Update: New Information on Diagnostic Testing for SARS-CoV-2
March 31, 2020
Thank you for your interest in development of diagnostics for SARS-CoV-2. On March 30, 2020, the FDA updated the frequently asked questions on diagnostic testing to include new and updated information on:
- When FDA authorizes a SARS-CoV-2 test for use at the point of care, does that mean it is CLIA waived?
- I am developing a COVID-19 assay that is a modification of a previously EUA authorized COVID-19 assay. Do I need to start from scratch with my validation or can I validate my test with a bridging study?
Recent News
- Nucleus Institute Convergence Point Groundbreaking
- EDWARDS LIFESCIENCES RECEIVES FDA APPROVAL FOR AUTUS VALVE
- Route 92 Medical Announces U.S. FDA Clearance for the FreeClimb® 46 Catheter with Tenzing® 4
- Owlet Announces Creation of Baby Safety Task Force to Educate, Innovate, and Advocate for Better Baby Safety Standards
- BD Celebrates 70 Years of Manufacturing, Innovation and Community Partnership in Sandy
- Freyya Closes Oversubscribed Pre-Seed Financing to Advance FDA Regulatory Milestones, Commercialization
